SAN
76.26
-1.73%↓
UCB
250.1
-3.1%↓
SHL.DE
40.38
-0.02%↓
ARGX
620.4
-1.02%↓
PHIA
24.97
-2.19%↓
SAN
76.26
-1.73%↓
UCB
250.1
-3.1%↓
SHL.DE
40.38
-0.02%↓
ARGX
620.4
-1.02%↓
PHIA
24.97
-2.19%↓
SAN
76.26
-1.73%↓
UCB
250.1
-3.1%↓
SHL.DE
40.38
-0.02%↓
ARGX
620.4
-1.02%↓
PHIA
24.97
-2.19%↓
SAN
76.26
-1.73%↓
UCB
250.1
-3.1%↓
SHL.DE
40.38
-0.02%↓
ARGX
620.4
-1.02%↓
PHIA
24.97
-2.19%↓
SAN
76.26
-1.73%↓
UCB
250.1
-3.1%↓
SHL.DE
40.38
-0.02%↓
ARGX
620.4
-1.02%↓
PHIA
24.97
-2.19%↓
24u
Huidig
Min
109.55
Max
114.3
Inkomsten | 250M 902M |
|---|---|
Verkoop | 63M 5.3B |
Dividendrendement | 1.34 |
Winstmarge | 16.961 |
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +31.63% upside |
Dividendrendement Sectorgemiddelde | 1.34% 2.25% |
|---|---|
Volgende Winsten | 13 mei 2026 |
Marktkapitalisatie | 98B |
|---|---|
Vorige openingsprijs | 113.77 |
Vorige sluitingsprijs | 110.05 |
By Acuity
29%
71%
72 / 351 Rangschikking in Healthcare
By Trading Central
Vertrouwen
Strong Bearish Evidence
121.15 / 123.55 Steun & Weerstand
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
5 mrt 2026, 06:28 UTC
Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings
DJ
Lezen
13 nov 2025, 13:40 UTC
Germany's Merck KGaA Shares Rise After Semiconductor, Pharma Demand Boost Results -- Update
DJ
Lezen
13 nov 2025, 06:24 UTC
Germany's Merck KGaA Posts Higher Earnings on Organic Growth Across Units
DJ
Lezen
5 mrt 2026, 08:40 UTC
Germany's Merck KGaA Issues Weaker-Than-Expected Guidance -- Market Talk
DJ
Lezen
5 mrt 2026, 06:00 UTC
Merck KGaA Sees 2026 Ebitda Before Special Items at EUR5.5B-EUR6B
DJ
Lezen
5 mrt 2026, 06:00 UTC
Merck KGaA Sees 2026 Adj EPS EUR7.10-Adj EPS EUR8
DJ
Lezen
5 mrt 2026, 06:00 UTC
Analysts Saw Merck KGaA 2025 Ebitda Before Special Items EUR6.1B
DJ
Lezen
5 mrt 2026, 06:00 UTC
Merck KGaA Sees 2026 Sales EUR20B-EUR21B
DJ
Lezen
5 mrt 2026, 06:00 UTC
Merck KGaA Sees 2026 Organic Net Sales Ranging From 1% Fall to 2% Rise
DJ
Lezen
5 mrt 2026, 06:00 UTC
Merck KGaA 2025 Adj EPS EUR8.34
DJ
Lezen
5 mrt 2026, 06:00 UTC
Analysts Saw Merck KGaA 2025 Net Sales at EUR21.14B
DJ
Lezen
5 mrt 2026, 06:00 UTC
Merck KGaA Expects Considerable Foreign-Exchange Headwinds in 2026
DJ
Lezen
5 mrt 2026, 06:00 UTC
Merck KGaA Keeps Dividend at EUR2.20 a Share
DJ
Lezen
5 mrt 2026, 06:00 UTC
Merck KGaA 2025 After-Tax Profit EUR2.615B
DJ
Lezen
5 mrt 2026, 06:00 UTC
Germany's Merck KGaA Says Organic Net Sales Grew 3.1% in 2025
DJ
Lezen
5 mrt 2026, 06:00 UTC
Merck KGaA 2025 Sales EUR21.1B
DJ
Lezen
5 mrt 2026, 06:00 UTC
Merck KGaA 2025 Ebitda Before Special Items EUR6.11B
DJ
Lezen
12 feb 2026, 15:20 UTC
Sanofi Shares Fall After CEO Change -- Update
DJ
Lezen
20 jan 2026, 09:54 UTC
DAVOS: Merck KGaA Not in a Hurry for M&A, CEO Says -- Market Talk
DJ
Lezen
13 nov 2025, 07:57 UTC
Germany's Merck KGaA Beats Expectations With Strong Results -- Market Talk
DJ
Lezen
13 nov 2025, 06:00 UTC
Merck KGaA Sees 2025 Ebitda Before Exceptional Items at EUR6B-EUR6.2B
DJ
Lezen
13 nov 2025, 06:00 UTC
Merck KGaA Narrows 2025 View To Sales EUR20.8B-EUR21.4B
DJ
Lezen
13 nov 2025, 06:00 UTC
Merck KGaA Sees 2025 Organic Ebitda Before Exceptional Items Growth of 5%-7%
DJ
Lezen
13 nov 2025, 06:00 UTC
Merck KGaA Had Guided for 2025 Organic Sales Growth of 2% to 5%
DJ
Lezen
13 nov 2025, 06:00 UTC
Merck KGaA Says Guidance Midpoint Remains Unchanged
DJ
Lezen
13 nov 2025, 06:00 UTC
Merck KGaA Had Guided for 2025 Organic Ebitda Before Exceptional Items Growth of 4%-8%
DJ
Lezen
13 nov 2025, 06:00 UTC
Merck KGaA Sees 2025 Organic Sales Growth of Around 3%
DJ
Lezen
13 nov 2025, 06:00 UTC
Merck KGaA 3Q After-Tax Profit EUR898M
DJ
Lezen
13 nov 2025, 06:00 UTC
Merck KGaA: 3Q Net Sales Rose 5.2% Organically With Solid Growth Across Sectors
DJ
Lezen
13 nov 2025, 06:00 UTC
Merck KGaA Narrows 2025 View
DJ
Lezen
Prijswijziging
By TipRanks
12 Maanden Prognose
Gemiddelde 149 EUR 31.63%
Hoogste 182 EUR
Laagste 130 EUR
Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merck KGaA - Dist. in de afgelopen 3 maanden.
By TipRanks
Buy
7 ratings
5
Buy
2
Hold
0
Sell
Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Merck KGaA - Dist in de afgelopen 3 maanden.
By Trading Central
Korte Termijn
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Gemiddeld Termijn
Neutral Evidence
The bullish and bearish events are balanced.
Lange Termijn
Bearish Evidence
All events are bearish.
By Acuity
Nieuwssentiment
Bullish Bewijs
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Boven gemiddelde
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$